The information included below was provided in connection with a presentation or publication on the date indicated and is qualified as such. Revolution Medicines disclaims any duty to update these materials.
Publication / Presentation
Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, RAS-GTP dependent oncogenic BRAF and NF1 loss
New research revealed an unexpected dependence of some cancer-causing forms of proteins in the RAS-MAP kinase pathway on the normal biochemical actions of SHP2. These functions can be disrupted by small molecule inhibitors of SHP2 designed by…Read more